Following this activity, participants should be able to: (1) Describe the pathophysiology and molecular pathology of neuroblastoma; (2) Describe the treatment approach for high-risk neuroblastoma and explain the role of anti-GD2 antibody; and (3) Discuss potential and promising immunological mechanisms and immunotherapeutic strategies in the current research pipeline.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedNov 5, 2025
-
Last day to claim creditOct 30, 2026 3 weeks left
-
Physicians’ Education Resource Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma
-
PVI, PeerView Institute for Medical Education Taking the High Road in NSCLC: Navigating Through Immunotherapy-Based Treatments to Optimize Outcomes
-
Clinical Care Options, LLC (dba Decera Clinical Education) Precision, Timing, and Teamwork in Melanoma Immunotherapy: Practical Strategies for Resectable and Metastatic Disease
-
National Comprehensive Cancer Network Recorded Presentation of NCCN Optimizing Patient Outcomes – From Mutation to Treatment: Understanding the Impact of New Targeted Therapies in Central Nervous System Cancers
-
National Comprehensive Cancer Network Recorded Presentation from Optimizing Patient Outcomes: The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving Immunotherapy Options
-
National Comprehensive Cancer Network Recorded Presentation from Optimizing Patient Outcomes – In a Blink of an Eye: Updates in Frontline Therapy with Blinatumomab for Pediatric Acute Lymphoblastic Leukemia
